{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:34:22Z","timestamp":1754152462983,"version":"3.41.2"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06332-y","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T21:30:58Z","timestamp":1747344658000},"page":"3523-3526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab efficacy for minimal residual disease eradication in philadelphia-negative acute lymphoblastic leukemia CD20+"],"prefix":"10.1007","volume":"104","author":[{"given":"Nicola","family":"Cecchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariarita","family":"Scium\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antony","family":"Ricchiuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Bosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola Stefano","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"3","key":"6332_CR1","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J et al (2018) Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia 32(3):606\u2013615. https:\/\/doi.org\/10.1038\/leu.2017.265","journal-title":"Leukemia"},{"issue":"5","key":"6332_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1001\/jamaoncol.2017.5305","volume":"4","author":"SE Siegel","year":"2018","unstructured":"Siegel SE, Stock W, Johnson RH et al (2018) Pediatric-Inspired treatment regimens for adolescents and young adults with Philadelphia Chromosome\u2013Negative acute lymphoblastic leukemia. JAMA Oncol 4(5):725\u2013734. https:\/\/doi.org\/10.1001\/jamaoncol.2017.5305","journal-title":"JAMA Oncol"},{"issue":"14","key":"6332_CR3","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","volume":"133","author":"W Stock","year":"2019","unstructured":"Stock W, Luger SM, Advani AS et al (2019) A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood 133(14):1548\u20131559. https:\/\/doi.org\/10.1182\/blood-2018-10-881961","journal-title":"Blood"},{"issue":"11","key":"6332_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-020-00383-2","volume":"10","author":"R Bassan","year":"2020","unstructured":"Bassan R, Pavoni C, Intermesoli T et al (2020) Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18\u201365 years: NILG ALL 10\/07. Blood Cancer J 10(11):119. https:\/\/doi.org\/10.1038\/s41408-020-00383-2","journal-title":"Blood Cancer J"},{"issue":"16","key":"6332_CR5","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1182\/bloodadvances.2022009596","volume":"7","author":"R Bassan","year":"2023","unstructured":"Bassan R, Chiaretti S, Della Starza I et al (2023) Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial. Blood Adv 7(16):4448\u20134461. https:\/\/doi.org\/10.1182\/bloodadvances.2022009596","journal-title":"Blood Adv"},{"issue":"25","key":"6332_CR6","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","volume":"113","author":"DA Thomas","year":"2009","unstructured":"Thomas DA, O\u2019Brien S, Jorgensen JL et al (2009) Prognostic significance of CD20 expression in adults with de Novo precursor B-lineage acute lymphoblastic leukemia. Blood 113(25):6330\u20136337. https:\/\/doi.org\/10.1182\/blood-2008-04-151860","journal-title":"Blood"},{"issue":"2","key":"6332_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3324\/haematol.2009.010306","volume":"95","author":"S Maury","year":"2010","unstructured":"Maury S, Huguet F, Leguay T et al (2010) Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 95(2):324\u2013328. https:\/\/doi.org\/10.3324\/haematol.2009.010306","journal-title":"Haematologica"},{"issue":"11","key":"6332_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","volume":"375","author":"S Maury","year":"2016","unstructured":"Maury S, Chevret S, Thomas X et al (2016) Rituximab in B-Lineage adult acute lymphoblastic leukemia. N Engl J Med 375(11):1044\u20131053. https:\/\/doi.org\/10.1056\/NEJMoa1605085","journal-title":"N Engl J Med"},{"issue":"8","key":"6332_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"issue":"9","key":"6332_CR10","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, G\u00f6kbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"9","key":"6332_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Maude SL, Rives S et al (2023) Three-Year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. JCO 41(9):1664\u20131669. https:\/\/doi.org\/10.1200\/JCO.22.00642","journal-title":"JCO"},{"issue":"17","key":"6332_CR12","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1200\/JCO.19.03024","volume":"38","author":"S Gupta","year":"2020","unstructured":"Gupta S, Wang C, Raetz EA et al (2020) Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: A report from the children\u2019s oncology group. J Clin Oncol 38(17):1897\u20131905. https:\/\/doi.org\/10.1200\/JCO.19.03024","journal-title":"J Clin Oncol"},{"issue":"23","key":"6332_CR13","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2009-11-253435","volume":"115","author":"P Stow","year":"2010","unstructured":"Stow P, Key L, Chen X et al (2010) Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 115(23):4657\u20134663. https:\/\/doi.org\/10.1182\/blood-2009-11-253435","journal-title":"Blood"},{"issue":"4","key":"6332_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(15)70082-3","volume":"16","author":"CH Pui","year":"2015","unstructured":"Pui CH, Pei D, Coustan-Smith E et al (2015) Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 16(4):465\u2013474. https:\/\/doi.org\/10.1016\/S1470-2045(15)70082-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"6332_CR15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/ijms21031054","volume":"21","author":"A Kruse","year":"2020","unstructured":"Kruse A, Abdel-Azim N, Kim HN et al (2020) Minimal residual disease detection in acute lymphoblastic leukemia. Int J Mol Sci 21(3):1054. https:\/\/doi.org\/10.3390\/ijms21031054","journal-title":"Int J Mol Sci"},{"issue":"10","key":"6332_CR16","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","volume":"104","author":"R Bassan","year":"2019","unstructured":"Bassan R, Br\u00fcggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S (2019) A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica 104(10):2028\u20132039. https:\/\/doi.org\/10.3324\/haematol.2018.201053","journal-title":"Haematologica"},{"issue":"14","key":"6332_CR17","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"issue":"3","key":"6332_CR18","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, D\u00fcll J, Yilmaz M et al (2018) Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol 93(3):371\u2013374. https:\/\/doi.org\/10.1002\/ajh.24987","journal-title":"Am J Hematol"},{"issue":"5","key":"6332_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1182\/blood.2023022330","volume":"143","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Haddad FG, Short NJ et al (2024) Phase 2 study of inotuzumab Ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood 143(5):417\u2013421. https:\/\/doi.org\/10.1182\/blood.2023022330","journal-title":"Blood"},{"key":"6332_CR20","doi-asserted-by":"publisher","first-page":"6119","DOI":"10.1182\/blood-2022-157937","volume":"140","author":"G Marconi","year":"2022","unstructured":"Marconi G, Piciocchi A, Chiaretti S et al (2022) Gimema ALL2418: interim analysis of a phase Iia study of feasibility and effectiveness of inotuzumab Ozogamicin in adult patients with B-Cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation. Blood 140:6119\u20136121. https:\/\/doi.org\/10.1182\/blood-2022-157937","journal-title":"Blood"},{"issue":"1","key":"6332_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41408-023-00813-x","volume":"13","author":"J Niu","year":"2023","unstructured":"Niu J, Qiu H, Xiang F et al (2023) CD19\/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study. Blood Cancer J 13(1):44. https:\/\/doi.org\/10.1038\/s41408-023-00813-x","journal-title":"Blood Cancer J"},{"issue":"24","key":"6332_CR22","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","volume":"28","author":"DA Thomas","year":"2010","unstructured":"Thomas DA, O\u2019Brien S, Faderl S et al (2010) Chemoimmunotherapy with a modified Hyper-CVAD and rituximab regimen improves outcome in de Novo Philadelphia Chromosome\u2013Negative precursor B-Lineage acute lymphoblastic leukemia. J Clin Oncol 28(24):3880\u20133889. https:\/\/doi.org\/10.1200\/JCO.2009.26.9456","journal-title":"J Clin Oncol"},{"issue":"6","key":"6332_CR23","first-page":"571","volume":"11","author":"AK Gupta","year":"2021","unstructured":"Gupta AK, Chopra A, Meena JP et al (2021) Rituximab added to standard chemotherapy and its effect on minimal residual disease during induction in CD20 positive pediatric acute lymphoblastic leukemia: a pilot RCT. Am J Blood Res 11(6):571\u2013579","journal-title":"Am J Blood Res"},{"issue":"2","key":"6332_CR24","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/sj.bmt.1702706","volume":"27","author":"BM J\u00e1ndula","year":"2001","unstructured":"J\u00e1ndula BM, Nomdedeu J, Mar\u00edn P, Vivancos P (2001) Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transpl 27(2):225\u2013227. https:\/\/doi.org\/10.1038\/sj.bmt.1702706","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"6332_CR25","first-page":"272","volume":"91","author":"A Claviez","year":"2006","unstructured":"Claviez A, Eckert C, Seeger K et al (2006) Rituximab plus chemotherapy in children with relapsed or refractory CD20-positive B-cell precursor acute lymphoblastic leukemia. Haematologica 91(2):272\u2013273.","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06332-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06332-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T07:59:48Z","timestamp":1753171188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06332-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6332"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06332-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}